Phase 3 study of Nexavar in the forefront of advanced lung cancer Non-small Cell-Unsatisfactory primary endpoint global … WAYNE, NJ and Emeryville, California, June 14 / PRNewswire-FirstCall / – Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc.
Skin and Hypersensitivity Reactions w/ Provigil (Jan. 2008)